Overview of the investigational e-TLIF procedure (2:04). The video is not downloaded until you press play.
Treat Neuropathic Pain at the Same Spinal Level as the Spine Surgery
In the e-TLIF™ procedure, a stimulation lead is placed at the dorsal root ganglion on the same spinal level being fused, during the fusion operation itself. SynerFuse calls the low-amplitude stimulation it is studying Ultra Low Energy (ULE™) Therapy. The full name of the procedure is Electric Transforaminal Lumbar Interbody Fusion.
Investigational device. The SynerFuse® e-TLIF™ procedure and the NeuroFuse® System are investigational. They are not cleared or approved by the FDA, are not available for sale, and are limited by federal (or United States) law to investigational use. Nothing on this page is medical advice or a claim of safety or effectiveness.
Our Technology
The SynerFuse® e-TLIF™ procedure incorporates input from the company’s medical team of surgeons and learnings from our completed proof-of-concept study. It is designed to let the NeuroFuse® System deliver Ultra Low Energy (ULE) therapy for direct nerve stimulation at the point of spine fusion. The NeuroFuse® System is designed to consist of an implantable pulse generator (IPG), a multi-channel lead to deliver electrical impulses from the IPG to the spine, a mobile device application for individualized programming of the IPG, and a clinician programmer for remote programming and monitoring.
Patient-Focused Integrated Solution
With the patented SynerFuse® e-TLIF™ procedure, the company is studying whether combining neuromodulation with fusion surgery, at the time the fusion is performed, can improve on the current treatment pathway. Whether it does so has not been established.
Surgeon-Centric
The lead is placed through the same incision as the fusion, in a single procedure. Designed by and for spine surgeons.
Fusion Hardware-Agnostic
Designed as an add-on to the fusion hardware a surgeon already prefers.
Broad Patent Coverage to Enable Novel Innovation
SynerFuse® holds twelve issued patents — nine in the United States, one in Canada and two in Australia — with further applications pending. The SynerFuse® IP strategy protects key aspects of our concept and technology to enable a novel approach to chronic back pain.
US 10,117,580 · 10,675,458 · 10,933,234 · 11,247,046 · 11,471,673 · 11,638,817 · 11,813,467 · 12,343,524 · 12,515,041; CA 3,062,728; AU 2019275582, AU 2021201832.
Medically reviewed by Rohan Lall, MD, Chief Medical Officer, SynerFuse. Last reviewed 24 August 2026.
